SKIP TO CONTENT
Drug & Device Products
FDAnews Books Library
Form 483s Database
Webinar Training Pass
eCFR and Guidances
» Two More Tropical Diseases Eligible for Priority Review Voucher in U.S.
Two More Tropical Diseases Eligible for Priority Review Voucher in U.S.
September 8, 2015
The U.S. Food and Drug Administration has added Chagas disease and neurocysticercosis to the list of treatments for tropical diseases eligible for priority review vouchers, bringing the number to 19.
To View This Article:
Forgot your password?
Subscribe To International Pharmaceutical Regulatory Monitor
Buy This Article Now
Add this article to your cart for $40.00
Successful Strategies for Digital Health in 2022: Who’s Doing Digital Well and How You Can Get Started
Statistics and Data for Regulatory Professionals and Attorneys: Product Performance Evidence Made Easy
Gene & Cell Therapy Regulation: Comparability and Other New Developments
Supply Chain Solutions: How the Pharmaceutical Industry Can End In-Bound Issue
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
MAGI's Clinical Research Hybrid Conference - 2022 East
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
BioFire Defense’s COVID-19 Test Gets FDA’s 510(k) Clearance
Pfizer/BioNTech to Test Omicron-Specific Version of Their COVID-19 Vaccine
Sensydia’s Cardiac Monitor Designated a Breakthrough Device
Rhode Island Reverses Course, Accepts Opioid Lawsuit Settlement
The Revised ICH E8:
A Guide to New Clinical Trial Requirements